A Study of Zoledronic Acid in the Prevention of Cancer Therapy-induced Bone Loss
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Primary Hormone Receptor Negative Breast Cancer in Premenopausal Women
Interventions: DRUG: Zoledronic Acid|DRUG: Placebo
Sponsor: Novartis Pharmaceuticals